Literature DB >> 27573173

Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy.

Kefang Liu1,2, Shuguang Tan3, Yan Chai3, Danqing Chen3, Hao Song4, Catherine Wei-Hong Zhang5, Yi Shi3, Jun Liu1,2, Wenjie Tan1,2, Jianxin Lyu1, Shan Gao6, Jinghua Yan7, Jianxun Qi3, George F Gao1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27573173      PMCID： PMC5223223          DOI： 10.1038/cr.2016.102

Source DB:  PubMed          Journal:  Cell Res        ISSN： 1001-0602            Impact factor:   25.617


× No keyword cloud information.
  8 in total

1.  A dimeric structure of PD-L1: functional units or evolutionary relics?

Authors:  Yong Chen; Peipei Liu; Feng Gao; Hao Cheng; Jianxun Qi; George F Gao
Journal:  Protein Cell       Date:  2010-02-06       Impact factor: 14.870

2.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.

Authors:  Thomas Powles; Joseph Paul Eder; Gregg D Fine; Fadi S Braiteh; Yohann Loriot; Cristina Cruz; Joaquim Bellmunt; Howard A Burris; Daniel P Petrylak; Siew-leng Teng; Xiaodong Shen; Zachary Boyd; Priti S Hegde; Daniel S Chen; Nicholas J Vogelzang
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

3.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Authors:  Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

Review 4.  Targeting T Cell Co-receptors for Cancer Therapy.

Authors:  Margaret K Callahan; Michael A Postow; Jedd D Wolchok
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

5.  The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors.

Authors:  David Yin-Wei Lin; Yoshimasa Tanaka; Masashi Iwasaki; Apostolos G Gittis; Hua-Poo Su; Bunzo Mikami; Taku Okazaki; Tasuku Honjo; Nagahiro Minato; David N Garboczi
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-14       Impact factor: 11.205

6.  Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.

Authors:  Krzysztof M Zak; Radoslaw Kitel; Sara Przetocka; Przemyslaw Golik; Katarzyna Guzik; Bogdan Musielak; Alexander Dömling; Grzegorz Dubin; Tad A Holak
Journal:  Structure       Date:  2015-10-22       Impact factor: 5.006

7.  Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging.

Authors:  Roy L Maute; Sydney R Gordon; Aaron T Mayer; Melissa N McCracken; Arutselvan Natarajan; Nan Guo Ring; Richard Kimura; Jonathan M Tsai; Aashish Manglik; Andrew C Kruse; Sanjiv S Gambhir; Irving L Weissman; Aaron M Ring
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-10       Impact factor: 11.205

8.  Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab.

Authors:  Zhenkun Na; Siok Ping Yeo; Sakshibeedu R Bharath; Matthew W Bowler; Esra Balıkçı; Cheng-I Wang; Haiwei Song
Journal:  Cell Res       Date:  2016-06-21       Impact factor: 25.617
  8 in total
  47 in total

1.  Strict Assembly Restriction of Peptides from Rabbit Hemorrhagic Disease Virus Presented by Rabbit Major Histocompatibility Complex Class I Molecule RLA-A1.

Authors:  Qingxu Zhang; Kefang Liu; Can Yue; Di Zhang; Dan Lu; Wenling Xiao; Peipei Liu; Yingze Zhao; Guolan Gao; Chunming Ding; Jianxin Lyu; William J Liu
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

2.  Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy.

Authors:  Xiaodong Wang; Xiaohui Yang; Chang Zhang; Yang Wang; Tianyou Cheng; Liqiang Duan; Zhou Tong; Shuguang Tan; Hangjie Zhang; Phei Er Saw; Yinmin Gu; Jinhua Wang; Yibi Zhang; Lina Shang; Yajuan Liu; Siyuan Jiang; Bingxue Yan; Rong Li; Yue Yang; Jie Yu; Yunzhao Chen; George Fu Gao; Qinong Ye; Shan Gao
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-11       Impact factor: 11.205

3.  A novel oncolytic virus engineered with PD-L1 scFv effectively inhibits tumor growth in a mouse model.

Authors:  Chuanjian Wu; Manman Wu; Minglong Liang; Sidong Xiong; Chunsheng Dong
Journal:  Cell Mol Immunol       Date:  2019-07-30       Impact factor: 11.530

4.  Molecular Basis of a Protective/Neutralizing Monoclonal Antibody Targeting Envelope Proteins of both Tick-Borne Encephalitis Virus and Louping Ill Virus.

Authors:  Xu Yang; Jianxun Qi; Ruchao Peng; Lianpan Dai; Ernest A Gould; George F Gao; Po Tien
Journal:  J Virol       Date:  2019-04-03       Impact factor: 5.103

Review 5.  Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?

Authors:  Markella Konstantinidou; Tryfon Zarganes-Tzitzikas; Katarzyna Magiera-Mularz; Tad A Holak; Alexander Dömling
Journal:  Angew Chem Int Ed Engl       Date:  2018-02-23       Impact factor: 15.336

6.  Avelumab-a new programmed death-ligand 1 inhibitor against advanced non-small cell lung cancer.

Authors:  Ignacio Gil-Bazo
Journal:  Transl Lung Cancer Res       Date:  2017-12

7.  Peptide-based PET quantifies target engagement of PD-L1 therapeutics.

Authors:  Dhiraj Kumar; Ala Lisok; Elyes Dahmane; Matthew McCoy; Sagar Shelake; Samit Chatterjee; Viola Allaj; Polina Sysa-Shah; Bryan Wharram; Wojciech G Lesniak; Ellen Tully; Edward Gabrielson; Elizabeth M Jaffee; John T Poirier; Charles M Rudin; Jogarao Vs Gobburu; Martin G Pomper; Sridhar Nimmagadda
Journal:  J Clin Invest       Date:  2019-01-07       Impact factor: 14.808

8.  Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint.

Authors:  Katarzyna Magiera-Mularz; Lukasz Skalniak; Krzysztof M Zak; Bogdan Musielak; Ewa Rudzinska-Szostak; Łukasz Berlicki; Justyna Kocik; Przemyslaw Grudnik; Dominik Sala; Tryfon Zarganes-Tzitzikas; Shabnam Shaabani; Alexander Dömling; Grzegorz Dubin; Tad A Holak
Journal:  Angew Chem Int Ed Engl       Date:  2017-09-26       Impact factor: 15.336

9.  Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers.

Authors:  Laith Al-Showbaki; Michelle B Nadler; Alexandra Desnoyers; Fahad A Almugbel; David W Cescon; Eitan Amir
Journal:  J Cancer       Date:  2021-05-19       Impact factor: 4.207

10.  Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer.

Authors:  Tianhang Zhai; Chao Wang; Yifeng Xu; Weifeng Huang; Zhijun Yuan; Tao Wang; Shuang Dai; Shaogang Peng; Tuling Pang; Wenchao Jiang; Yuhua Huang; Yuefeng Zou; Yingda Xu; Joanne Sun; Xinjiang Gong; Jinping Zhang; Andy Tsun; Bin Li; Xiaoniu Miao
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.